Ocular Therapeutix Inc. Stock
€6.20
Your prediction
Ocular Therapeutix Inc. Stock
Pros and Cons of Ocular Therapeutix Inc. in the next few years
Pros
Cons
Performance of Ocular Therapeutix Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Ocular Therapeutix Inc. | -1.260% | -1.806% | 27.347% | 35.802% | 47.712% | -48.350% | 48.865% |
| Orasure Tech | -2.130% | -3.093% | -12.150% | -17.904% | -49.530% | -56.642% | -53.053% |
| scPharmaceuticals | 0.510% | -5.340% | 8.333% | -56.425% | -32.174% | -32.174% | - |
| SI-BONE Inc | 0.840% | 3.478% | -8.462% | -52.016% | -37.368% | -54.924% | - |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Ocular Therapeutics, Inc., trading under the US symbol OCUL, operates in the Healthcare Equipment & Supplies industry. Upon observing the company's financial statements, it seems that Ocular Therapeutics is not generating enough profitability. However, their financial health has shown some fluctuations over the years. In the following analysis, the financial aspects of Ocular Therapeutics will be examined thoroughly, revealing the potential strengths and weaknesses in the company's financial position.
Rising Revenue: The total revenue of Ocular Therapeutics has been increasing year-on-year. Between 2020 and 2022, the company's total revenue grew from $17.4 million to $51.49 million. This shows that the company has been successful in boosting its sales, which is a positive indication for future growth.
Research & Development Investment: Ocular Therapeutics has consistently devoted a significant portion of its expenditure to research and development activities. The research and development expenses have increased from $28.69 million in 2020 to $53.46 million in 2022. This demonstrates the company's commitment to innovation and product improvement, which could lead to better market positioning and long-term growth prospects.
Comments
